Last reviewed · How we verify
A Phase I Study of [111In-DTPA-D-Phe]-Octreotide in Patients With Refractory Malignancies Expressing Somatostatin Receptors
RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of indium In 111 pentetreotide in treating patients who have refractory cancer.
Details
| Lead sponsor | Yale University |
|---|---|
| Phase | Phase 1 |
| Status | TERMINATED |
| Enrolment | 35 |
| Start date | 1996-10 |
| Completion | 2004-08 |
Conditions
- Brain and Central Nervous System Tumors
- Childhood Langerhans Cell Histiocytosis
- Gastrointestinal Carcinoid Tumor
- Head and Neck Cancer
- Intraocular Melanoma
- Islet Cell Tumor
- Kidney Cancer
- Lung Cancer
- Melanoma (Skin)
- Neoplastic Syndrome
Interventions
- indium In 111 pentetreotide
Countries
United States